TME Pharma N.V. Stock

Equities

ALTME

NL0015000YE1

Biotechnology & Medical Research

Market Closed - Euronext Paris 11:29:27 2024-06-14 EDT 5-day change 1st Jan Change
0.205 EUR -5.09% Intraday chart for TME Pharma N.V. -10.87% -10.87%

Financials

Sales 2022 - Sales 2023 - Capitalization 1.22M 1.14M 1.67M
Net income 2022 -15M -14.02M -20.6M Net income 2023 -6M -5.61M -8.24M EV / Sales 2022 -
Net cash position 2022 548K 512K 753K Net cash position 2023 1.08M 1.01M 1.48M EV / Sales 2023 -
P/E ratio 2022
-0.09 x
P/E ratio 2023
-0.17 x
Employees 13
Yield 2022 *
-
Yield 2023
-
Free-Float 9.94%
More Fundamentals * Assessed data
Dynamic Chart
1 day-5.09%
1 week-10.87%
Current month-20.54%
1 month-15.64%
3 months-33.33%
6 months-12.39%
Current year-10.87%
More quotes
1 week
0.20
Extreme 0.2
0.23
1 month
0.20
Extreme 0.2
0.26
Current year
0.20
Extreme 0.2
0.44
1 year
0.19
Extreme 0.1902
1.95
3 years
0.19
Extreme 0.1902
40.98
5 years
0.19
Extreme 0.1902
123.00
10 years
0.19
Extreme 0.1902
2 200.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 54 10-04-30
Director of Finance/CFO - 99-12-31
Investor Relations Contact - 17-12-31
Members of the board TitleAgeSince
Director/Board Member 53 20-06-29
Chairman 76 16-08-31
Director/Board Member 58 21-06-23
More insiders
Date Price Change Volume
24-06-14 0.205 -5.09% 331,915
24-06-13 0.216 -4.21% 71,559
24-06-12 0.2255 +2.73% 124,619
24-06-11 0.2195 -4.57% 193,784
24-06-10 0.23 0.00% 101,925

Real-time Euronext Paris, June 14, 2024 at 11:29 am

More quotes
TME Pharma N.V. is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. The company specializes in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Its unique technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma N.V.'s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. Its clinical programs in glioblastoma and pancreatic cancer have delivered very promising results and further development is planned.
Calendar
More about the company

Chiffre d''affaires - Rate of surprise